CD8A and neoplasm: Of note, MAGE-A-specific CD8 T cells can be seen in the peripheral blood of ESCC patients, and these T cells respond to MAGE-A3-loaded DCs to target MAGE-A3+ tumor cells (Huang and Fu, 2019).